RCPA Quality Assurance Programs Pty Ltd Congress Grant
Aim: Bcl‐2 is a proto‐oncogene known to be a negative regulator of apoptosis which confers prolonged cell survival and possibly contributes to tumorigenesis. A number of studies have been carried out to estimate and analyse its expression in renal tumours but the results have been conflicting. The aim of this study was to determine the expression and intensity of Bcl‐2 in renal cell carcinomas (RCCs).
Methods: Fifty‐nine cases of formalin‐fixed, paraffin‐embedded tissue samples of RCCs were studied immunohistochemically for bcl‐2 (monoclonal mouse antihuman bcl‐2 oncoprotein antibody, clone 124; DakoCytomation) expression and intensity of staining (score 0–4).
Results: The results showed that 55 cases of clear cell RCC were negative for bcl‐2. However, one case each of papillary (2+) and chromophobe RCC (4+) and two cases of RCC with sarcomatoid transformation (3+ and 4+, respectively) showed positivity.
Discussion: Clear cell RCC is not associated with expression of bcl‐2 except for the papillary and chromophobe variants and RCC with sarcomatoid transformation.
Huang A, Fone PD, Gandour-Edwards R, Devere White RW, Low RK. Immunohistochemical analysis of Bcl-2 protein expression in renal cell carcinoma. J Urol
1999; 162: 610–3